Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Hopes To Market Provigil With Anesta Actiq To Oncologists

Executive Summary

Cephalon hopes eventually to market the narcolepsy treatment Provigil to oncologists using the sales force that details Anesta's breakthrough cancer pain treatment Actiq, following a merger between the two companies.

You may also be interested in...



Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%

Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon

Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%

Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon

Ilex Resembles Recent Biotech Acquisition Targets As Campath Nears Market

Ilex Oncology appears to fit the profile of recently acquired companies within the biotechnology industry.

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel